The medication is a Nonsteroidal Anti-inflammatory Drug (NSAID) applied across domains where additional symptomatic support is needed. It is commonly used to help with symptoms related to pain, inflammation, and fever, and is relevant for physical discomfort and conditions presenting with systemic or localized symptoms.

This therapeutic support is commonly used for a range of conditions characterized by periods of heightened symptoms, including chronic issues like rheumatoid arthritis and osteoarthritis, as well as acute episodes such as gouty arthritis flare-ups, discomfort from musculoskeletal injuries (sprains and strains), and postoperative pain.

The general use of the medication involves providing support that helps ease the overall symptom burden. It is used when symptoms create noticeable functional strain or become more disruptive during flare-ups. This is applicable in clinical settings that involve acute or unstable symptom patterns, such as managing the discomfort associated with primary dysmenorrhea (menstrual cramping) or helping to ease fever when it is linked to inflammatory states.

---

Quick Fact: Relief for Inflammatory Discomfort This medicine is commonly used to help manage symptoms related to inflammatory or irritative states, such as pain and swelling, in conditions like tendonitis, bursitis, and joint flares, supporting general well-being during symptomatic phases.

---

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Ketoprofen (Ketonal): Official Regulatory Status

Official regulatory documents define strict criteria for who is eligible to use this medicine. The standard approved population for Ketoprofen is adults, with some oral formulations approved for adolescents aged 16 and older. Use in children under 16 years, particularly for oral formulations, is generally not recommended as safety and efficacy have not been established across all pediatric age groups.

Absolute Non-Eligibility (Contraindications)

Ketoprofen is formally contraindicated and must not be used by patients who have a known history of hypersensitivity or allergic reactions to aspirin, ketoprofen, or other NSAIDs. Use is also strictly prohibited in individuals with severe, uncontrolled heart, liver, or kidney impairment, or those with active gastrointestinal bleeding, perforation, or peptic ulceration. Additionally, the medicine is contraindicated during the third trimester of pregnancy and for patients undergoing peri-operative pain management for CABG surgery.

Restricted or Conditional Use

Older adults are at a higher risk of adverse reactions, particularly serious gastrointestinal events, and require cautious use. Pregnant individuals in the first and second trimesters should only use the medicine if clearly necessary, and at the lowest effective dose for the shortest duration. Use is also not recommended for females who are breastfeeding.

The official interaction profile for Ketoprofen (the active ingredient in Ketonal) is defined by risks primarily related to bleeding, renal function, and altered drug exposure, resulting in strict regulatory constraints.

Contraindicated Combinations and Major Restrictions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including high-dose salicylates and COX-2 selective inhibitors, is prohibited due to the augmented risk of serious gastrointestinal adverse events. Use is also formally contraindicated for the treatment of perioperative pain related to Coronary Artery Bypass Graft (CABG) surgery. The combination with high-dose Methotrexate (over 15 mg per week) is prohibited, as official data states Ketoprofen can reduce its renal clearance, leading to elevated exposure and toxicity risk.

Pharmacokinetic and Pharmacodynamic Interactions

Concomitant use with Lithium is documented to raise its plasma levels due to a reduction in renal clearance. Co-administration with oral anticoagulants (e.g., Warfarin), anti-platelet agents, SSRIs, and corticosteroids carries a documented additive pharmacodynamic risk of hemorrhage and gastrointestinal complications. Interaction with diuretics or ACE inhibitors may reduce their blood pressure-lowering effect and carries a risk of acute renal failure. Alcohol intake is officially noted to increase the risk of gastrointestinal adverse effects. In patients with chronic liver disease, Ketoprofen’s pharmacokinetics are altered, potentially resulting in higher blood levels. Low-dose Methotrexate requires a minimum 12-hour separation from Ketoprofen administration.

Non-Selective Inhibition of COX Enzymes

The primary action of Ketoprofen is the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, targeting both COX-1 and COX-2 isoforms. This molecular action suppresses the Arachidonic Acid Cascade, thereby reducing the synthesis of key downstream mediators, mainly prostaglandins (PGE2).

---

️ Modulation of Nociceptive and Vascular Responses

This decreased synthesis of prostaglandins produces two major physiological outcomes. Peripherally, it results in the diminished chemical sensitization of nociceptors (pain-sensing nerve endings), which increases the required activation energy for peripheral nociception. The mechanism also suppresses prostaglandin-driven vasodilation and vascular permeability at the cellular level.

---

Central Thermoregulatory Adjustment

In addition to its peripheral effects, the mechanism includes activity within the Central Nervous System (CNS). By inhibiting prostaglandin synthesis within the hypothalamus, Ketoprofen successfully suppresses the signaling molecule responsible for resetting the body’s internal thermoregulatory set-point upwards. This central modulation modifies the central set-point, facilitating the return of core temperature regulation.

The medication Ketonal, which contains the active ingredient Ketoprofen, is administered through multiple routes, including oral, topical (cutaneous), and rectal methods, depending on the specific dosage form.

Official Dosing and Administration

Oral dosing patterns are differentiated for maintenance and acute use. For chronic administration, such as for long-term conditions, the immediate-release (IR) capsules are typically prescribed in a divided regimen of 50 mg four times per day or 75 mg three times per day. The total dose must not exceed the maximum daily limit of 300 mg. In contrast, the extended-release (ER) formulation is administered as a single 200 mg dose once daily and is not recommended for the treatment of acute pain. For short-term acute use, the IR form is administered as needed (PRN) in doses of 25 mg to 50 mg every 6 to 8 hours.

The administration rules specify that taking the oral form with food slows the rate of drug absorption, though the total systemic bioavailability remains unaltered. Topical administration involves applying 2 g to 4 g of the gel 2 to 4 times per day, which must be accompanied by gentle and prolonged massage into the skin. Topical use is generally limited to up to seven days, and the use of occlusive dressings over the application site is avoided.

Population-Specific Use

Dose adjustment is a required procedural step for certain populations. Older adults must be initiated at the lower end of the adult therapeutic range. Additionally, maximum daily dose limits are imposed for patients with documented renal or hepatic impairment, and the use of the drug in children under 15 years of age is generally not established.

Research Evidence / Overview of Studies for Ketonal (Ketoprofen)

---

Evidence for Use in Chronic Arthritis Conditions

The research base for Ketoprofen includes Randomized Controlled Trials (RCTs) and systematic reviews that have explored patterns of change in symptoms related to long-term conditions like rheumatoid arthritis and osteoarthritis. These studies were used in research exploring how symptoms change over time when patients are dealing with conditions characterized by functional limitations and fluctuating symptoms. Researchers measured specific outcomes related to physical discomfort and changes in overall daily functioning.

Studies reported measurements of outcomes for the medication when evaluated against a placebo and in head-to-head research contexts. However, the research base for chronic use is subject to certain limitations. Comparative evidence is often lacking against a comprehensive range of alternatives, meaning research examined patterns against only a limited number of other agents.

Evidence for Use in Acute Pain and Inflammation

Research examining the evaluation of Ketoprofen for acute and temporary pain, such as postoperative discomfort or pain from traumatic musculoskeletal injuries, relies heavily on single-dose Randomized Controlled Trials and subsequent Cochrane Reviews. These studies monitored outcomes describing episodic or acute changes, such as the initial change in symptom intensity and the time until patients sought additional symptom management.

Trials were observed in settings focusing on research exploring short-term symptom changes. Data show patterns related to the time it takes to report initial changes in perceived discomfort after a single dose. What remains uncertain in this context is that the evidence is heavily concentrated on short-term symptom changes, often tracking effects for only a few hours post-dose. There is limited information for long-term outcomes relevant to prolonged acute use over several days.

Extended Treatment and Follow-up Durations

Research on Ketoprofen was evaluated in settings involving both short-term follow-ups (for acute discomfort) and long-term observations (for chronic arthritis). Studies focusing on chronic conditions involving periods of heightened symptoms have follow-up durations relevant to ongoing symptom assessment. The evidence highlights what is known—and what is still uncertain—about the persistence of observed symptom patterns over time. Specifically, there is limited information for long-term outcomes that look beyond the initial trial periods, particularly for acute indications where research focused on temporary physiological imbalance.

Key Limitations and Areas of Research Uncertainty

Key limitations in the evidence base include the focus on short-term symptom changes for acute evaluations, with long-term effects not fully established across all indications. In comparative research, the comparative evidence is lacking against the full range of alternative treatments, making broad relative efficacy conclusions difficult to draw solely from the existing data. Furthermore, for some specific formulations or indications, sample sizes were modest in initial trials, and certain evidence quality varies across studies, leading to findings that may be heterogeneous when combined. The evidence describes group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Safety of ketoprofen compared with ibuprofen and diclofenac: a systematic review and meta-analysis (2016)

Common questions about Ketonal(NSAID) (FAQ)

Q: What Ketonal is generally used for, besides pain?

A: According to official product information, Ketonal (Ketoprofen) belongs to a class of medicines that act as an analgesic (pain reliever), an antipyretic (fever reducer), and an anti-inflammatory agent. Its overall purpose is to manage pain, reduce fever, and help alleviate symptoms associated with inflammation.

Q: Is Ketonal known to cause drowsiness?

A: Official adverse reaction listings show that side effects related to the nervous system, such as dizziness and headache, have been reported. Drowsiness has also been documented in some instances. Due to the potential for these nervous system effects, caution is generally recommended regarding operating machinery or driving until the individual knows how the medicine affects them.

Q: Is Ketonal generally considered suitable for children?

A: Regulatory documents state that the use of oral formulations is not generally established or recommended for children under 16 years of age. This is because safety and effectiveness have not been sufficiently established across all pediatric age groups. Eligibility for use is restricted to adults and older adolescents.

Q: What is the maximum amount of time someone can take Ketonal without consulting a professional?

A: Official documentation differentiates between short-term use for acute symptoms and maintenance dosing for chronic conditions. Topical formulations typically have a limit of up to seven days. The precise duration for oral use is defined by a health professional based on the individual's needs.

Q: What if I miss a dose of Ketonal, what is the general recommendation?

A: Patient information documents typically state that if a dose is missed, the guidance is to proceed with the next scheduled dose as originally planned. It is officially advised that patients should not take a double dose to compensate for the one they missed.

Q: Are generic versions of Ketonal available?

A: Ketonal is the commercial name for the drug, whose active ingredient is Ketoprofen. Ketoprofen is the generic name for the compound and, like many medications, is available from various manufacturers.

Q: Is Ketonal the same as other common over-the-counter pain relievers?

A: Ketonal is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). While other common pain relievers are also NSAIDs, Ketoprofen is generally classified as a prescription-only medicine in many regions, which differentiates its official availability status from common over-the-counter products.

Q: Does Ketonal come in different forms, like capsules, tablets, or gels?

A: Yes, official product information confirms that Ketoprofen is manufactured in various pharmaceutical forms. These include capsules, tablets (immediate and extended-release), topical gels, and solutions for injection.

Q: How quickly does Ketonal typically start working?

A: According to the official pharmacokinetic data, which describes how the body handles the drug, the time it takes to reach the peak concentration in the blood is relatively fast. This peak concentration is described as typically being reached within approximately 0.5 to 2 hours after taking the immediate-release oral formulation.

Q: How long do the effects of Ketonal usually last?

A: The dosing schedule for acute pain relief is typically every 6 to 8 hours, which provides an indication of the usual duration of symptomatic relief. The elimination half-life of Ketoprofen is short, generally around 1 to 4 hours, meaning it is quickly processed by the body.

Q: Can Ketonal be taken on an empty stomach?

A: Regulatory guidance notes that taking the oral form with food slows its absorption rate. However, official documents often advise that taking NSAIDs with food or milk may help reduce the chance of gastrointestinal upset.

Q: What are the signs of an allergic reaction to Ketonal?

A: Official warnings include the risk of severe reactions like anaphylaxis or severe skin reactions. Signs that have been documented to occur include swelling of the face, difficulty breathing, rash, hives, or blistering of the skin.

Q: Are there interactions between Ketonal and herbal supplements?

A: Regulatory documents specifically warn about interactions with alcohol and certain prescription medications. Regulatory materials emphasize the importance of communicating all concomitant products, including any non-prescription or herbal supplements, to a healthcare professional.

Q: Can Ketonal affect fertility or pregnancy?

A: Official documents state that the medicine is formally contraindicated during the third trimester of pregnancy. Furthermore, regulatory guidance states that NSAIDs as a class may impair female fertility and official information indicates that they should generally be avoided by women attempting to conceive.

Q: What are the official recommendations for stopping the use of Ketonal?

A: For short-term use, abrupt cessation is often described as being possible once the acute symptoms have resolved. For chronic conditions, a healthcare professional typically provides guidance on adjusting or stopping the medication.

Q: What are the ingredients in Ketonal aside from the active substance?

A: The active substance is Ketoprofen. Regulatory documents list the other components as inactive ingredients, or excipients, which may include substances like lactose, magnesium stearate, and other agents that help form the tablet or capsule.

Q: Can Ketonal cause headaches?

A: Yes, official adverse reaction documents classify headache and dizziness as frequently reported adverse effects related to Nervous System Disorders.

Q: Can Ketonal be crushed or split?

A: Specific administration rules are provided for each formulation. Generally, extended-release capsules or enteric-coated products are not recommended to be crushed or split, as this can alter the intended absorption profile and potentially increase the risk of side effects.

Q: Are there specific food restrictions while taking Ketonal?

A: Regulatory documents explicitly warn against the co-administration of Ketoprofen with alcohol, as this increases the risk of gastrointestinal adverse effects. No other specific food restrictions (beyond general meal timing) are commonly listed in major regulatory documents.

Q: Does Ketonal cause water retention or swelling?

A: Official adverse reaction documents confirm that fluid retention and edema (swelling caused by excess fluid) have been reported in association with the use of NSAIDs like Ketoprofen.

Q: What research exists about Ketonal and dental procedures?

A: The research base includes studies on acute and temporary pain, such as postoperative discomfort. While dental procedures are a common source of acute pain, official documents typically refer to broader categories like general postoperative pain or traumatic musculoskeletal injuries.

Q: Is Ketonal useful for period pain?

A: Yes, the official indications for use typically include the management of mild to moderate pain. This category of use covers primary dysmenorrhea, which is the medical term for common period pain.

Q: Do studies support the use of Ketonal for joint pain?

A: Studies and official information indicate that the research base includes randomized controlled trials and reviews examining symptom patterns related to chronic arthritis conditions. These conditions, such as rheumatoid arthritis and osteoarthritis, are characterized by joint pain.

Q: Are there different strengths of Ketonal tablets?

A: Yes, official product information confirms that Ketoprofen is available in different strengths. These may include various strengths for immediate-release capsules and a higher strength for extended-release tablets, depending on the specific product formulation.

Q: What is the official duration of treatment usually recommended for acute pain?

A: For acute, temporary pain, the drug is administered as needed. Official regulatory guidance advises that the lowest effective dose should be used for the shortest duration necessary to achieve symptomatic relief.

Q: Is it normal to feel dizzy after taking Ketonal?

A: Yes, official adverse reaction documents list dizziness as a frequently reported adverse effect. This is classified as a nervous system disorder reported in association with the medicine's use.

Storage and Disposal Instructions for Ketoprofen (NSAID)

Ketoprofen must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from environmental factors by storing it away from heat, moisture, and direct light. It is explicitly required that the product not be frozen.

Container and Child-Safety

The product should be kept in a closed container and remain tightly closed to maintain integrity. When dispensed, it must include a child-resistant closure and be stored securely out of the reach of children.

Disposal of Unused Medicine

Outdated medicine or product that is no longer needed must be discarded. Disposal of unused or expired Ketoprofen should follow the proper disposal procedures as advised by a healthcare professional.